Core Viewpoint - Elanco Animal Health Incorporated has released its 2024 Impact Report, emphasizing its commitment to enhancing animal care and the well-being of those who care for them through a new framework focused on four key communities of impact [1][2][3] Group 1: Commitment to Animals - Elanco's strong portfolio and high-impact innovations drive the company's mission to improve animal lives [4] - Key innovations such as Zenrelia, Credelio Quattro, and Pradalex generated $461 million in revenue in 2024, exceeding the target of $420 million to $450 million [7] - The company ranked as the 1 retail parasiticide dispenser in the U.S. and expanded global retail offerings [7] Group 2: Commitment to Customers - Elanco aims to advocate for and earn the trust of customers while solving significant challenges to create value [5] - The company has launched new veterinary-formulated pet supplements under the Advantage family umbrella [7] Group 3: Commitment to Society - Elanco is dedicated to improving public health through animal health initiatives and safeguarding the food system [6] - The company donated over $400,000 worth of products to support animal health and well-being [7] - Elanco's UpLook database helps U.S. dairy farmers earn around $10 million in net returns from carbon credit reductions [7] Group 4: Commitment to Employees - Elanco promotes a purpose-driven culture that encourages ownership, growth, and well-being among its employees [8] - The company achieved a 71% Employee Engagement Score, reflecting a 4% increase from the previous year [11] - Over 26,000 volunteer hours were recorded in 2024, contributing an estimated value of $870,000 across 1,100 global organizations [11] Group 5: Future Outlook - Elanco invites stakeholders to explore the full 2024 Impact Report and is committed to advancing its purpose of making life better for animals, customers, society, and employees [9]

All right. So, just to for just for fairness, you didn't take the the survey. You're not one of these survey respondents.So, we're kind of getting a live read from you. Um, I want to go to tariffs. So, we again 41% said tariffs will directly impact their cost.For when it comes to your company, again, pet and animal medicine. Um, how are tariffs impacting your business. Look, as a global company, tariffs remain dynamic and we continue to watch it.But we have a global base. uh while about 50% of our business ...

PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO. “I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by ear ...

Group 1 - Phibro Animal Health (NASDAQ: PAHC) announced a significant acquisition from Zoetis (ZTS) aimed at driving business momentum [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in IPOs, mergers & acquisitions, earnings reports, and corporate capital allocation [1] - The service covers approximately 10 major events monthly to find optimal investment opportunities [1]

Core Viewpoint - Virbac has appointed Paul Martingell as the new CEO, effective September 1, 2025, bringing extensive international experience in consumer health and pharmaceuticals to the role [1][5]. Group 1: Leadership and Experience - Paul Martingell, aged 45, has over 25 years of international experience, particularly in consumer health, consumer goods, and pharmaceuticals [1][2]. - His previous roles include significant positions at Ernst & Young, Reckitt Benckiser, and Novartis Consumer Healthcare, where he was part of the executive committee overseeing the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses [2][3]. - Martingell has demonstrated leadership in developing diverse teams and leading successful transformations, focusing on growth and performance [3]. Group 2: Strategic Vision - Martingell expressed enthusiasm for joining Virbac and aims to innovate and create a lasting impact in the animal health sector [4]. - The board of directors believes that his background and leadership style will contribute to the long-term development of Virbac by providing a new perspective [5]. Group 3: Transition and Acknowledgment - The board of directors acknowledged the contributions of Habib Ramdani, who served as interim CEO prior to Martingell's appointment [6].

Key Takeaways Phibro's Animal Health unit grew 42% with a standout 68% rise in MFAs and other product sales in fiscal Q3. Phibro saw 40% of fiscal Q3 revenues from international markets like Latin America, India and Southeast Asia. PAHC's Mineral Nutrition and Performance Products units posted double-digit sales growth recovery.Phibro Animal Health Corporation’s (PAHC) focus on advancing its Animal Health business is poised to drive growth in the upcoming quarters. The company’s global growth prospects lo ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Dev ...

Core Viewpoint - Elanco Animal Health has received a positive opinion from the European Medicines Agency for its product Zenrelia, which is expected to receive marketing authorization in the EU within 60 days [1][2]. Group 1: Product Details - Zenrelia (ilunocitinib) is effective in treating pruritus associated with allergic dermatitis and clinical manifestations of atopic dermatitis in dogs [2]. - The product has already been approved in markets outside the United States, including Brazil, Canada, Japan, and the United States, with additional approvals anticipated in Australia and the United Kingdom in 2025 [3]. Group 2: Regulatory Milestones - The positive opinion from the CVMP is based on the quality, safety, and efficacy data submitted by Elanco, demonstrating a favorable benefit-risk balance [2]. - Elanco has conducted a head-to-head non-inferiority study against the current market leader, yielding positive results [3]. Group 3: Market Launch Expectations - The company expects to launch Zenrelia shortly after receiving marketing authorization, with product supply anticipated in the market before the end of the third quarter of 2025 [3].

Elanco Animal Health Incorporated (ELAN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power ...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsMay, 31 20258 390 660Gross total of voting rights : 12 705 976Net total* of voting rights : ...